These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 30476750)

  • 1. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.
    Corti F; Nichetti F; Raimondi A; Niger M; Prinzi N; Torchio M; Tamborini E; Perrone F; Pruneri G; Di Bartolomeo M; de Braud F; Pusceddu S
    Cancer Treat Rev; 2019 Jan; 72():45-55. PubMed ID: 30476750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Inhibitors in Advanced Biliary Tract Cancers.
    Wu CE; Chen MH; Yeh CN
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30682771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
    Grunt TW; Mariani GL
    Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
    Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
    Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
    Li H; Zeng J; Shen K
    Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham J
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
    Ghayad SE; Cohen PA
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.
    Houédé N; Pourquier P
    Pharmacol Ther; 2015 Jan; 145():1-18. PubMed ID: 24929024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
    Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
    Blachly JS; Baiocchi RA
    Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
    Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
    J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.